Literature DB >> 14580364

Expression of prostanoid receptors in human lower segment pregnant myometrium.

Andreas Leonhardt1, Alexander Glaser, Markus Wegmann, Reinhard Hackenberg, Rolf M Nüsing.   

Abstract

Prostanoids, especially prostaglandin (PG) E(2), are important mediators of uterine relaxation and contractions during gestation and parturition. Inhibitors of PG formation as well as PG analogues are used to modulate uterine tonus. So far, only limited data are available regarding the expression of prostanoid receptors in human pregnant myometrium. In the present study, the expression of the receptors for PGE(2) (EP1, EP2, EP3, EP4), PGF(2alpha) (FP), prostacyclin (IP), and thromboxane A(2) (TP) in human pregnant myometrium was studied by RT-PCR, in situ hybridization and immunohistochemistry. Myometrial tissue was obtained from five women at term and not in labour and from two women who delivered preterm. Tissue specimens were excised from the upper edge of the transverse lower uterine segment incision. In all tissues analysed, EP1, EP2, EP3, EP4, FP, TP and IP receptor mRNA and protein was detected. mRNA expression for PGD(2) (DP) receptor was not detected in the majority of tissue specimens. EP1, EP2, EP4, IP, TP and FP receptor protein was detected on myometrial smooth muscle cells, whereas EP3 receptor protein was only expressed by stromal and endothelial cells. In situ hybridization experiments yielded similar results. The expression of the EP2 receptor mRNA was inversely related to gestational age. We suggest that the contractile effect of PGE(2) at term is probably mediated directly by the EP1 receptor expressed in myometrial smooth muscle cells and indirectly by the EP3 receptor expressed in stromal cells and a decrease in EP2 receptor expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580364     DOI: 10.1016/s0952-3278(03)00113-3

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

1.  Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.

Authors:  Oliver Pohl; Line Marchand; Jean-Pierre Gotteland; Simon Coates; Jörg Täubel; Ulrike Lorch
Journal:  Br J Clin Pharmacol       Date:  2018-06-05       Impact factor: 4.335

2.  Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition.

Authors:  Kristina M Fetalvero; Peisheng Zhang; Maureen Shyu; Benjamin T Young; John Hwa; Roger C Young; Kathleen A Martin
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

3.  Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype.

Authors:  N Foudi; L Kotelevets; L Louedec; G Leséche; D Henin; E Chastre; X Norel
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

4.  Expression and functional maintenance of volume-regulated anion channels in myometrial smooth muscles of pregnant mice.

Authors:  Kazutaka Yamada; Wei-Guang Ding; Mariko Omatsu-Kanbe; Futoshi Toyoda; Shunichiro Tsuji; Daisuke Katsura; Fuminori Kimura; Hiroshi Matsuura; Takashi Murakami
Journal:  Exp Anim       Date:  2021-11-16

5.  Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors.

Authors:  Agnieszka Blitek; Mateusz Luba; Magdalena Szymanska
Journal:  Animals (Basel)       Date:  2022-08-30       Impact factor: 3.231

6.  Tocolytic effect of a selective FP receptor antagonist in rodent models reveals an innovative approach to the treatment of preterm labor.

Authors:  André Chollet; Enrico Gillio Tos; Rocco Cirillo
Journal:  BMC Pregnancy Childbirth       Date:  2007-06-01       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.